Shiraev 201817
|
22,427
|
Systemic review of 3 cohort (prospective and retrospective)
|
P: elderly > 65 years
90% of patients were on ASA
I: PPIs users
C: non-PPIs users
O: all-cause mortality and CV events
|
Less than
1 year
|
1 year
|
Xie 201918
|
214,467
|
A longitudinal observational cohort study
PPIs (n=157,625)
H2RAs (n=56,842)
|
P: elderly > 65 years, men, white
I: PPIs user
C: H2Ras users
O: all-cause mortality, CV and kidney diseases specific mortality
|
4.6 years
(median)
|
10 years
|
Moayyedi 2019 19
|
17, 598
|
RCT
Harm outcomes were secondary outcomes
|
P: elderly > 65 years, stable CV disease
I: PPIs users
C: placebo
O: all-cause mortality
|
Less than
3 years
|
3 years
|